Incidence rates of renal flares and hazard ratios comparing antimalarial users and non-users
| . | Pooled study population (n = 3225) . | |
|---|---|---|
| . | AMA use . | AMA non-use . |
| n = 2173 . | n = 1052 . | |
| Renal flares during follow-up, n (%) | 116 (5.3) | 76 (7.2) |
| Person-years of follow-up | 2077.1 | 977.5 |
| Rate of renal flares per 1000 person-years (95% CI) | 55.8 (46.1, 67.0) | 77.7 (61.3, 97.3) |
| Unadjusted HR | 0.7 (0.5–1.0) P = 0.026 | 1.0 (reference) |
| Adjusted HR | 0.7 (0.6–0.8) P < 0.001 | 1.0 (reference) |
| . | Pooled study population (n = 3225) . | |
|---|---|---|
| . | AMA use . | AMA non-use . |
| n = 2173 . | n = 1052 . | |
| Renal flares during follow-up, n (%) | 116 (5.3) | 76 (7.2) |
| Person-years of follow-up | 2077.1 | 977.5 |
| Rate of renal flares per 1000 person-years (95% CI) | 55.8 (46.1, 67.0) | 77.7 (61.3, 97.3) |
| Unadjusted HR | 0.7 (0.5–1.0) P = 0.026 | 1.0 (reference) |
| Adjusted HR | 0.7 (0.6–0.8) P < 0.001 | 1.0 (reference) |
| . | Renal BILAG A–D at baseline subgroup (n = 1761) . | |
|---|---|---|
| . | AMA use . | AMA non-use . |
| . | n = 1209 . | n = 552 . |
| Renal flares during follow-up, n (%) | 111 (9.2) | 70 (12.7) |
| Person-years of follow-up | 1094.6 | 480.4 |
| Rate of renal flares per 1000 person-years (95% CI) | 101.4 (83.4, 122.1) | 145.7 (113.6, 184.1) |
| Unadjusted HR | 0.7 (0.5–0.9) P = 0.017 | 1.0 (reference) |
| Adjusted HR | 0.7 (0.6–0.8) P < 0.001 | 1.0 (reference) |
| . | Renal BILAG A–D at baseline subgroup (n = 1761) . | |
|---|---|---|
| . | AMA use . | AMA non-use . |
| . | n = 1209 . | n = 552 . |
| Renal flares during follow-up, n (%) | 111 (9.2) | 70 (12.7) |
| Person-years of follow-up | 1094.6 | 480.4 |
| Rate of renal flares per 1000 person-years (95% CI) | 101.4 (83.4, 122.1) | 145.7 (113.6, 184.1) |
| Unadjusted HR | 0.7 (0.5–0.9) P = 0.017 | 1.0 (reference) |
| Adjusted HR | 0.7 (0.6–0.8) P < 0.001 | 1.0 (reference) |
| . | Renal BILAG E at baseline subgroup (n = 1464) . | |
|---|---|---|
| . | AMA use . | AMA non-use . |
| . | n = 964 . | n = 500 . |
| Renal flares during follow-up, n (%) | 5 (0.5) | 6 (1.2) |
| Person-years of follow-up | 982.4 | 497.1 |
| Rate of renal flares per 1000 person-years (95% CI) | 5.1 (1.7, 11.9) | 12.1 (4.4, 26.3) |
| . | Renal BILAG E at baseline subgroup (n = 1464) . | |
|---|---|---|
| . | AMA use . | AMA non-use . |
| . | n = 964 . | n = 500 . |
| Renal flares during follow-up, n (%) | 5 (0.5) | 6 (1.2) |
| Person-years of follow-up | 982.4 | 497.1 |
| Rate of renal flares per 1000 person-years (95% CI) | 5.1 (1.7, 11.9) | 12.1 (4.4, 26.3) |
Incidence rate and hazard rations are presented for the pooled study population, and for the subgroups of patients with renal BILAG A–D and renal BILAG E at baseline.
Cox regression models were adjusted for age, sex, ethnicity, extra-renal clinical SLEDAI-2K score, SDI score, proteinuria, anti-dsDNA positivity, low C3, low C4, use of glucocorticoids, and use of immunosuppressants. The model for the pooled population was additionally adjusted for current or previous renal involvement (renal BILAG A–D vs BILAG E at baseline).
BILAG: British Isles Lupus Assessment Group; BLM: belimumab; IV: intravenous; SC: subcutaneous; SDI: SLICC/ACR Damage Index; SLEDAI-2K: systemic lupus erythematosus disease activity index 2000.
Incidence rates of renal flares and hazard ratios comparing antimalarial users and non-users
| . | Pooled study population (n = 3225) . | |
|---|---|---|
| . | AMA use . | AMA non-use . |
| n = 2173 . | n = 1052 . | |
| Renal flares during follow-up, n (%) | 116 (5.3) | 76 (7.2) |
| Person-years of follow-up | 2077.1 | 977.5 |
| Rate of renal flares per 1000 person-years (95% CI) | 55.8 (46.1, 67.0) | 77.7 (61.3, 97.3) |
| Unadjusted HR | 0.7 (0.5–1.0) P = 0.026 | 1.0 (reference) |
| Adjusted HR | 0.7 (0.6–0.8) P < 0.001 | 1.0 (reference) |
| . | Pooled study population (n = 3225) . | |
|---|---|---|
| . | AMA use . | AMA non-use . |
| n = 2173 . | n = 1052 . | |
| Renal flares during follow-up, n (%) | 116 (5.3) | 76 (7.2) |
| Person-years of follow-up | 2077.1 | 977.5 |
| Rate of renal flares per 1000 person-years (95% CI) | 55.8 (46.1, 67.0) | 77.7 (61.3, 97.3) |
| Unadjusted HR | 0.7 (0.5–1.0) P = 0.026 | 1.0 (reference) |
| Adjusted HR | 0.7 (0.6–0.8) P < 0.001 | 1.0 (reference) |
| . | Renal BILAG A–D at baseline subgroup (n = 1761) . | |
|---|---|---|
| . | AMA use . | AMA non-use . |
| . | n = 1209 . | n = 552 . |
| Renal flares during follow-up, n (%) | 111 (9.2) | 70 (12.7) |
| Person-years of follow-up | 1094.6 | 480.4 |
| Rate of renal flares per 1000 person-years (95% CI) | 101.4 (83.4, 122.1) | 145.7 (113.6, 184.1) |
| Unadjusted HR | 0.7 (0.5–0.9) P = 0.017 | 1.0 (reference) |
| Adjusted HR | 0.7 (0.6–0.8) P < 0.001 | 1.0 (reference) |
| . | Renal BILAG A–D at baseline subgroup (n = 1761) . | |
|---|---|---|
| . | AMA use . | AMA non-use . |
| . | n = 1209 . | n = 552 . |
| Renal flares during follow-up, n (%) | 111 (9.2) | 70 (12.7) |
| Person-years of follow-up | 1094.6 | 480.4 |
| Rate of renal flares per 1000 person-years (95% CI) | 101.4 (83.4, 122.1) | 145.7 (113.6, 184.1) |
| Unadjusted HR | 0.7 (0.5–0.9) P = 0.017 | 1.0 (reference) |
| Adjusted HR | 0.7 (0.6–0.8) P < 0.001 | 1.0 (reference) |
| . | Renal BILAG E at baseline subgroup (n = 1464) . | |
|---|---|---|
| . | AMA use . | AMA non-use . |
| . | n = 964 . | n = 500 . |
| Renal flares during follow-up, n (%) | 5 (0.5) | 6 (1.2) |
| Person-years of follow-up | 982.4 | 497.1 |
| Rate of renal flares per 1000 person-years (95% CI) | 5.1 (1.7, 11.9) | 12.1 (4.4, 26.3) |
| . | Renal BILAG E at baseline subgroup (n = 1464) . | |
|---|---|---|
| . | AMA use . | AMA non-use . |
| . | n = 964 . | n = 500 . |
| Renal flares during follow-up, n (%) | 5 (0.5) | 6 (1.2) |
| Person-years of follow-up | 982.4 | 497.1 |
| Rate of renal flares per 1000 person-years (95% CI) | 5.1 (1.7, 11.9) | 12.1 (4.4, 26.3) |
Incidence rate and hazard rations are presented for the pooled study population, and for the subgroups of patients with renal BILAG A–D and renal BILAG E at baseline.
Cox regression models were adjusted for age, sex, ethnicity, extra-renal clinical SLEDAI-2K score, SDI score, proteinuria, anti-dsDNA positivity, low C3, low C4, use of glucocorticoids, and use of immunosuppressants. The model for the pooled population was additionally adjusted for current or previous renal involvement (renal BILAG A–D vs BILAG E at baseline).
BILAG: British Isles Lupus Assessment Group; BLM: belimumab; IV: intravenous; SC: subcutaneous; SDI: SLICC/ACR Damage Index; SLEDAI-2K: systemic lupus erythematosus disease activity index 2000.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
